Skip to main content
. 2020 Oct 31;10(1):109–118. doi: 10.1002/cam4.3575

Figure 3.

Figure 3

Clinical Response by Tumor Type in the RECIST Efficacy‐Evaluable Population (N = 13)a. aOnly patients who had measurable disease at baseline and at least one post‐baseline tumor assessment were included in the efficacy‐evaluable population. One patient did not have a post‐baseline assessment of target lesions and is, therefore, not included in this figure. Abbreviations: BRCA, breast cancer susceptibility gene; RECIST, Response Evaluation Criteria in Solid Tumors